2024
Outcomes and Recurrence Rates Among Patients With Provoked and Cryptogenic Cerebral Venous Thrombosis
Al Kasab S, Almallouhi E, Shu L, Kicielinski K, Salehi Omran S, Liebeskind D, Zubair A, Vedovati M, Paciaroni M, Antonenko K, Heldner M, de Havenon A, Henninger N, Yaghi S. Outcomes and Recurrence Rates Among Patients With Provoked and Cryptogenic Cerebral Venous Thrombosis. Neurology Clinical Practice 2024, 15: e200381. PMID: 39399562, PMCID: PMC11464219, DOI: 10.1212/cpj.0000000000200381.Peer-Reviewed Original ResearchRisk of recurrent venous thromboembolismRecurrent venous thromboembolismCerebral venous thrombosisVenous thromboembolismFemale patientsVenous thrombosisBaseline characteristicsOutcome of cerebral venous thrombosisRate of recurrent venous thromboembolismProvoking factorsRare cause of strokeTransient provoking factorsKaplan-Meier survival analysisDuration of anticoagulationOutcomes of patientsMann-Whitney <i>Cause of strokeConsecutive patientsRare causeRecurrence rateMale patientsMulticenter studyRetrospective databaseStandard treatmentCox regression
2023
791-P: Comparing the Real-World Effects of Once-Weekly GLP-1 RAs and DPP-4 Inhibitors on Ischemic Stroke and Myocardial Infarction in Individuals with T2D and ASCVD
TAN X, LIANG Y, RAJPURA J, YEDIGAROVA L, NOONE J, XIE L, DE HAVENON A. 791-P: Comparing the Real-World Effects of Once-Weekly GLP-1 RAs and DPP-4 Inhibitors on Ischemic Stroke and Myocardial Infarction in Individuals with T2D and ASCVD. Diabetes 2023, 72 DOI: 10.2337/db23-791-p.Peer-Reviewed Original ResearchAtherosclerotic cardiovascular diseaseGLP-1 RAsMyocardial infarctionDPP-4iIschemic strokeCardiovascular eventsNovo NordiskGlucagon-like peptide-1 receptor agonistsWeekly glucagon-like peptide-1 receptor agonistMajor adverse cardiovascular eventsPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsRisk of MINew adult usersAdverse cardiovascular eventsRetrospective cohort studyPeptidase-4 inhibitorsDPP-4 inhibitorsType 2 diabetesReal-world evidenceDrug discontinuationBaseline characteristicsCohort studyOptum ClinformaticsReceptor agonist